Enanta completed enrollment for RSVPEDs, a Phase 2 study of zelicapavir in pediatric RSV patients, and completed the EDP-323 Phase 2a Challenge Study in RSV. Topline data for both studies are expected in Q4 2024 and late Q3 2024, respectively.